Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:ENTA

Enanta Pharmaceuticals Q4 2026 Earnings Date & Estimates

Enanta Pharmaceuticals logo
$11.67 +0.26 (+2.28%)
Closing price 03:58 PM Eastern
Extended Trading
$11.68 +0.01 (+0.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enanta Pharmaceuticals is estimated to report Q4 2026 earnings on Monday, November 16, 2026. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q4 2026
Announcement Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Enanta Pharmaceuticals in Q4 2026

Enanta Pharmaceuticals is expected to post earnings of -$0.7240 per share on revenue of $14.62 million. In the same quarter a year earlier Enanta Pharmaceuticals reported -$0.87 per share on revenue of $15.13 million. Enanta Pharmaceuticals last reported on August 10, 2026, posting -$0.67 per share and missing the -$0.5095 consensus estimate. Enanta Pharmaceuticals has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.7240
Expected Revenue
$14.62 million
Prior-Year EPS
-$0.87
Prior-Year Revenue
$15.13 million
Expected Revenue Growth
-3.3%

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
-$0.67 (Missed by -$0.1605)
Last Quarter Revenue
$14.36 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q4 2026 Call

Enanta Pharmaceuticals Q4 2026 Earnings FAQ

Enanta Pharmaceuticals (NASDAQ:ENTA) is estimated to report Q4 2026 earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Enanta Pharmaceuticals' Q4 2026 earnings conference call is scheduled for Monday, November 16, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Enanta Pharmaceuticals to post earnings of -$0.7240 per share for Q4 2026.

The consensus revenue estimate for Enanta Pharmaceuticals is $14.62 million for Q4 2026.

Enanta Pharmaceuticals Earnings Headlines

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Breaks Below Two Hundred Day Moving Average - Here's Why
October 20 at 3:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31137974
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
October 13, 2026  |  marketscreener.comM
I waited 13 years for this setup
Gold more than doubled after breaking a 13-year range in April 2024, then fell over 20 percent in its worst quarter since 2013. This isn't the first time. In 2008, gold dropped hard mid-supercycle, and three years later it neared 2,000 dollars. The biggest gains came from an overlooked backdoor gold play that ran as high as 1,915 percent during that cycle. Ross Givens believes this supercycle is far from over.tc pixel
October 20 at 1:00 AM  |  Traders Agency (Ad)
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Lowered by Wall Street Zen
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106652
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
August 10, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260810427925/en/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-june-30-2026/
Enanta Faces Patent Setback in Paxlovid Litigation
June 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/enanta-faces-patent-setback-in-paxlovid-litigation?utm_source=marketbeat.com&utm_medium=referral
See More Enanta Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA) is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection. Enanta also discovered paritaprevir, another HCV antiviral used in earlier AbbVie combination regimens. These products have helped establish the company’s expertise in antiviral drug discovery, although commercialization and marketing activities are conducted primarily through partners.

Founded in 1995 and headquartered in Watertown, Massachusetts, Enanta conducts research and clinical development activities through its U.S. operations and collaborations with pharmaceutical companies. The company is led by Jay R. Luly, Ph.D., who serves as president and chief executive officer.

View Enanta Pharmaceuticals Profile
Earnings Tools